Home > Publications database > The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. > print

001     132796
005     20240229105032.0
024 7 _ |a 10.1002/humu.23411
|2 doi
024 7 _ |a pmid:29460995
|2 pmid
024 7 _ |a 1059-7794
|2 ISSN
024 7 _ |a 1098-1004
|2 ISSN
024 7 _ |a altmetric:33504513
|2 altmetric
037 _ _ |a DKFZ-2018-00440
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Colombo, Mara
|0 0000-0001-5465-354X
|b 0
245 _ _ |a The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity.
260 _ _ |a New York, NY [u.a.]
|c 2018
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1659613165_16657
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Although the spliceogenic nature of the BRCA2 c.68-7T > A variant has been demonstrated, its association with cancer risk remains controversial. In this study, we accurately quantified by real-time PCR and digital PCR (dPCR), the BRCA2 isoforms retaining or missing exon 3. In addition, the combined odds ratio for causality of the variant was estimated using genetic and clinical data, and its associated cancer risk was estimated by case-control analysis in 83,636 individuals. Co-occurrence in trans with pathogenic BRCA2 variants was assessed in 5,382 families. Exon 3 exclusion rate was 4.5-fold higher in variant carriers (13%) than controls (3%), indicating an exclusion rate for the c.68-7T > A allele of approximately 20%. The posterior probability of pathogenicity was 7.44 × 10-115 . There was neither evidence for increased risk of breast cancer (OR 1.03; 95% CI 0.86-1.24) nor for a deleterious effect of the variant when co-occurring with pathogenic variants. Our data provide for the first time robust evidence of the nonpathogenicity of the BRCA2 c.68-7T > A. Genetic and quantitative transcript analyses together inform the threshold for the ratio between functional and altered BRCA2 isoforms compatible with normal cell function. These findings might be exploited to assess the relevance for cancer risk of other BRCA2 spliceogenic variants.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Lòpez-Perolio, Irene
|b 1
700 1 _ |a Meeks, Huong D
|b 2
700 1 _ |a Caleca, Laura
|b 3
700 1 _ |a Parsons, Michael T
|b 4
700 1 _ |a Li, Hongyan
|b 5
700 1 _ |a De Vecchi, Giovanna
|b 6
700 1 _ |a Tudini, Emma
|b 7
700 1 _ |a Foglia, Claudia
|b 8
700 1 _ |a Mondini, Patrizia
|b 9
700 1 _ |a Manoukian, Siranoush
|b 10
700 1 _ |a Behar, Raquel
|b 11
700 1 _ |a Garcia, Encarna B Gómez
|b 12
700 1 _ |a Meindl, Alfons
|b 13
700 1 _ |a Montagna, Marco
|b 14
700 1 _ |a Niederacher, Dieter
|b 15
700 1 _ |a Schmidt, Ane Y
|b 16
700 1 _ |a Varesco, Liliana
|b 17
700 1 _ |a Wappenschmidt, Barbara
|b 18
700 1 _ |a Bolla, Manjeet K
|b 19
700 1 _ |a Dennis, Joe
|b 20
700 1 _ |a Michailidou, Kyriaki
|b 21
700 1 _ |a Wang, Qin
|b 22
700 1 _ |a Aittomäki, Kristiina
|b 23
700 1 _ |a Andrulis, Irene L
|b 24
700 1 _ |a Anton-Culver, Hoda
|b 25
700 1 _ |a Arndt, Volker
|0 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
|b 26
700 1 _ |a Beckmann, Matthias W
|b 27
700 1 _ |a Beeghly-Fadel, Alicia
|b 28
700 1 _ |a Benitez, Javier
|b 29
700 1 _ |a Boeckx, Bram
|b 30
700 1 _ |a Bogdanova, Natalia V
|b 31
700 1 _ |a Bojesen, Stig E
|b 32
700 1 _ |a Bonanni, Bernardo
|b 33
700 1 _ |a Brauch, Hiltrud
|0 P:(DE-HGF)0
|b 34
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 35
700 1 _ |a Burwinkel, Barbara
|0 P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf
|b 36
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 37
700 1 _ |a Conroy, Don M
|b 38
700 1 _ |a Couch, Fergus J
|b 39
700 1 _ |a Cox, Angela
|b 40
700 1 _ |a Cross, Simon S
|b 41
700 1 _ |a Czene, Kamila
|b 42
700 1 _ |a Devilee, Peter
|b 43
700 1 _ |a Dörk, Thilo
|b 44
700 1 _ |a Eriksson, Mikael
|b 45
700 1 _ |a Fasching, Peter A
|b 46
700 1 _ |a Figueroa, Jonine
|b 47
700 1 _ |a Fletcher, Olivia
|b 48
700 1 _ |a Flyger, Henrik
|b 49
700 1 _ |a Gabrielson, Marike
|b 50
700 1 _ |a García-Closas, Montserrat
|b 51
700 1 _ |a Giles, Graham G
|b 52
700 1 _ |a González-Neira, Anna
|b 53
700 1 _ |a Guénel, Pascal
|b 54
700 1 _ |a Haiman, Christopher A
|b 55
700 1 _ |a Hall, Per
|b 56
700 1 _ |a Hamann, Ute
|0 P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b
|b 57
700 1 _ |a Hartman, Mikael
|b 58
700 1 _ |a Hauke, Jan
|b 59
700 1 _ |a Hollestelle, Antoinette
|b 60
700 1 _ |a Hopper, John L
|b 61
700 1 _ |a Jakubowska, Anna
|b 62
700 1 _ |a Jung, Audrey
|0 P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9
|b 63
|u dkfz
700 1 _ |a Kosma, Veli-Matti
|b 64
700 1 _ |a Lambrechts, Diether
|b 65
700 1 _ |a Le Marchand, Loid
|b 66
700 1 _ |a Lindblom, Annika
|b 67
700 1 _ |a Lubinski, Jan
|b 68
700 1 _ |a Mannermaa, Arto
|b 69
700 1 _ |a Margolin, Sara
|b 70
700 1 _ |a Miao, Hui
|b 71
700 1 _ |a Milne, Roger L
|b 72
700 1 _ |a Neuhausen, Susan L
|b 73
700 1 _ |a Nevanlinna, Heli
|b 74
700 1 _ |a Olson, Janet E
|b 75
700 1 _ |a Peterlongo, Paolo
|b 76
700 1 _ |a Peto, Julian
|b 77
700 1 _ |a Pylkäs, Katri
|b 78
700 1 _ |a Sawyer, Elinor J
|b 79
700 1 _ |a Schmidt, Marjanka K
|b 80
700 1 _ |a Schmutzler, Rita K
|b 81
700 1 _ |a Schneeweiss, Andreas
|b 82
700 1 _ |a Schoemaker, Minouk J
|b 83
700 1 _ |a See, Mee Hoong
|b 84
700 1 _ |a Southey, Melissa C
|b 85
700 1 _ |a Swerdlow, Anthony
|b 86
700 1 _ |a Teo, Soo H
|b 87
700 1 _ |a Toland, Amanda E
|b 88
700 1 _ |a Tomlinson, Ian
|b 89
700 1 _ |a Truong, Thérèse
|b 90
700 1 _ |a van Asperen, Christi J
|b 91
700 1 _ |a van den Ouweland, Ans M W
|b 92
700 1 _ |a van der Kolk, Lizet E
|b 93
700 1 _ |a Winqvist, Robert
|b 94
700 1 _ |a Yannoukakos, Drakoulis
|b 95
700 1 _ |a Zheng, Wei
|b 96
700 1 _ |a Investigators, kConFab/AOCS
|b 97
|e Collaboration Author
700 1 _ |a Dunning, Alison M
|b 98
700 1 _ |a Easton, Douglas F
|b 99
700 1 _ |a Henderson, Alex
|b 100
700 1 _ |a Hogervorst, Frans B L
|b 101
700 1 _ |a Izatt, Louise
|b 102
700 1 _ |a Offitt, Kenneth
|b 103
700 1 _ |a Side, Lucy E
|b 104
700 1 _ |a van Rensburg, Elizabeth J
|b 105
700 1 _ |a Embrace, Study
|b 106
700 1 _ |a Hebon, Study
|b 107
700 1 _ |a McGuffog, Lesley
|b 108
700 1 _ |a Antoniou, Antonis C
|b 109
700 1 _ |a Chenevix-Trench, Georgia
|b 110
700 1 _ |a Spurdle, Amanda B
|b 111
700 1 _ |a Goldgar, David E
|b 112
700 1 _ |a Hoya, Miguel de la
|b 113
700 1 _ |a Radice, Paolo
|b 114
773 _ _ |a 10.1002/humu.23411
|g Vol. 39, no. 5, p. 729 - 741
|0 PERI:(DE-600)1498165-8
|n 5
|p 729 - 741
|t Human mutation
|v 39
|y 2018
|x 1059-7794
909 C O |p VDB
|o oai:inrepo02.dkfz.de:132796
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 34
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 35
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 36
|6 P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 37
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 57
|6 P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 63
|6 P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HUM MUTAT : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b HUM MUTAT : 2015
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)L801-20160331
|k L801
|l DKTK Tübingen
|x 1
920 1 _ |0 I:(DE-He78)G110-20160331
|k G110
|l Präventive Onkologie
|x 2
920 1 _ |0 I:(DE-He78)C080-20160331
|k C080
|l Molekulare Epidemiologie
|x 3
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 4
920 1 _ |0 I:(DE-He78)B072-20160331
|k B072
|l Molekulargenetik des Mammakarzinoms
|x 5
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)L801-20160331
980 _ _ |a I:(DE-He78)G110-20160331
980 _ _ |a I:(DE-He78)C080-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)B072-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21